Cargando…
Nusinersen in type 0 spinal muscular atrophy: should we treat?
A male infant affected by type 0 SMA with one copy of SMN2 received early treatment with Nusinersen at the age of 13 days. He showed mild motor improvement 2 months after treatment started but despite also showing some minimal respiratory improvement, required tracheostomy at the age of 4 months and...
Autores principales: | Tiberi, Eloisa, Costa, Simonetta, Pane, Marika, Priolo, Francesca, de Sanctis, Roberto, Romeo, Domenico, Tiziano, Francesco D., Conti, Giorgio, Vento, Giovanni, Mercuri, Eugenio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732235/ https://www.ncbi.nlm.nih.gov/pubmed/33147378 http://dx.doi.org/10.1002/acn3.51126 |
Ejemplares similares
-
Reply to: The need for evidence‐based treatment decisions in spinal muscular atrophy type 0
por: Mercuri, Eugenio, et al.
Publicado: (2021) -
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
por: Pera, Maria Carmela, et al.
Publicado: (2021) -
Nusinersen and Spinal Muscular Atrophies: Where are we in 2020?
por: Khadilkar, Satish V., et al.
Publicado: (2020) -
Nusinersen efficacy data for 24‐month in type 2 and 3 spinal muscular atrophy
por: Pane, Marika, et al.
Publicado: (2022) -
Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)